CRYOPORT, INC. (NASDAQ: CYRX)
THIRD QUARTER 2026 IN REVIEW
November 5, 2026

Important information

This document provides a review of Cryoport, Inc.'s operational performance during the third quarter (Q3) of 2026, covering the three-month period ended September 30, 2026, and a general business outlook, supplementing our Q3 2026 earnings release. It is designed to be read by interested parties before the regularly scheduled quarterly conference call, which, for this quarter, is scheduled for 5:00 p.m. ET on Thursday, November 5, 2026. Therefore, the conference call will be in the format of a questions and answers session and will address any questions the investment community has regarding the Company's results.

Conference Call Information

Date:	November 5, 2026
Time:	5:00 p.m. ET
Dial-in numbers:	1-800-717-1738 (U.S.), 1-646-307-1865 (International)
Confirmation code:	Request the "Cryoport Call" or Conference ID: 1107312
Live webcast:	'Investor Relations' section at www.cryoportinc.com or click here. Please allow 10 minutes prior to the call to visit this site to download and install any necessary audio software.


Questions and answers will be recorded and available approximately three hours after completion of the live event on the Investor Relations section of the Company's website at www.cryoportinc.com for a limited time. To access the replay of the questions and answers, please follow this link. A dial-in replay of the call will also be available to those interested, until November 12, 2026. To access the replay, dial 1-844-512-2921 (United States) or 1-412-317-6671 (International) and enter replay entry code: 1107312#.

THIRD QUARTER 2026 FINANCIAL RESULTS OVERVIEW


Business Description	***Cryoport, Inc. (Nasdaq: CYRX)*** *is a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, with an emphasis on regenerative medicine and cell and gene therapies. We support biopharmaceutical companies, contract manufacturers (CDMOs), contract research organizations (CROs), developers, and researchers with a comprehensive suite of services and products designed to minimize risk and maximize reliability across the temperature-controlled integrated supply chain. With innovation, regulatory compliance, and agility at our core we are* ***"Enabling the Future of Medicine™."***
Client Examples	• **Biopharma/Pharma:** *Bristol Myers Squibb, Crispr Therapeutics, Gilead, Iovance, J&J, Lonza, Thermo Fisher Scientific, Vertex Pharma* • **Animal Health:** *Boehringer Ingelheim, Elanco, Genus PLC, Zoetis* • **Reproductive Medicine:** *Carrot Fertility, CCRM, Inception (MyEggBank), Pinnacle Fertility, TMRW/Reprotech,*
Revenue	Q3 2026: $50.2 million (+14% YoY)
Number of Global Clinical Trials Currently Supported	788 clinical trials - 99 in Phase 3
2026 Full Year Revenue Guidance	$197.0 - $199.0 million (Updated)
Cash, Cash Equivalents & Short-Term Investments	$393.1 million
CEO	Jerrell Shelton

Continued Strength in Core CGT business


Cryoport delivered third quarter revenue of $50.2 million, reflecting continued momentum across our core cell and gene therapy (CGT) business. Revenue from commercial CGT clients increased 20% year-over-year, driven by **strong 29% growth in Life Sciences Services revenue supporting commercial CGTs, as total Life Sciences Services revenue grew 18%**, underscoring the strength of our integrated platform and the growing demand for our solutions.



For the third quarter, Life Sciences Services revenue represented 57% of our total revenue, demonstrating the value and scalability of our expanding services platform. **BioLogistics Solutions revenue increased 16% year-over-year** in Q3 2026, driven by continued commercial therapies development, and clinical trial progress within the CGT market. **BioStorage/BioServices revenue grew 25% year-over-year**, reflecting another quarter of strong demand for our expanded, integrated services offering, which provides seamless, secure handling of temperature-sensitive materials across our global network.



Our Life Sciences Products business posted revenue growth of 8% for the quarter. MVE Biological Solutions (MVE) continues to demonstrate its global market leadership in cryogenic systems, benefiting from strong demand across animal health markets and continued adoption of our Fusion® line of cryogenic freezers. Beyond its revenue contribution, MVE remains a core strategic asset that generates consistent cash flow while creating valuable synergies with our Life Sciences Services platform.




Raising Full Year 2026 Outlook

Our strong year-to-date performance, combined with expanding support of commercial therapies, deepening customer relationships, a robust clinical trial pipeline, and continued demand for MVE's industry-leading products, gives us confidence in our outlook. As a result, we are **increasing our full-year 2026 revenue guidance to a range of $197.0 million to $199.0 million**.

The Company's 2026 guidance is dependent on its current business and expectations, which may be impacted by, among other things, factors that are outside of our control, such as national economic factors, the global macroeconomic and geopolitical environment, supply chain constraints, inflationary pressures, tariffs and other trade restrictions and/or the effects of foreign currency fluctuations, as well as the other factors described in the Company's filings with the Securities and Exchange Commission ("SEC"), including in the "Risk Factors" section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC.


CGT Market - Continuing to Expand

According to a recent report by Fortune Business Insights, the global CGT market size is projected to grow from $16.45 billion in 2026 to $143.55 billion by 2034, exhibiting a CAGR of 31.10% during this timeframe.




Source: https://www.fortunebusinessinsights.com/cell-and-gene-therapy-market-114130

This projected growth is expected to be fueled in part by increasing investments in the sector, as year-to-date financings for CGT companies have significantly outpaced prior year levels. According to a recent study by the Alliance for Regenerative Medicine, total sector financings were estimated at $11.3 billion in the first nine months of 2026, compared to $7.9 billion during the comparable prior year period and $11.2 billion in total for 2025.




Supportive of this growth, year-to-date biopharma funding trends also continued to show considerable year-over-year improvement through the third quarter. Total biopharma equity investments for the first nine months of 2026 were $55.3 billion, an increase of approximately 83% compared to $30.3 billion during the same period in 2025, which is indicative of an ongoing biopharma demand recovery.

Biopharma Equity Investments ($ bil.)



Source: FactSet, RBC; Note: Includes venture, IPO, and equity follow-on; Data as of 10/1/2026; Percentage represents year-over-year change.

During the quarter, we further strengthened our leadership position within the CGT ecosystem, ending the period **supporting 23 commercial therapies**. We also exited the quarter with a record clinical trial pipeline of 788 global trials, a net increase of 43 clinical trials over the prior year, with 99 of them in Phase 3 and 370 in Phase 2. This also represents approximately 70% of the CGT industry's clinical trials. Approximately 59% of the global clinical trials supported by Cryoport were autologous cell therapies, 29% were allogeneic cell therapies, 6% were gene therapies, and the remaining trials were vaccines, biologics and other trials. We believe this industry-leading position will continue to drive commercial revenue growth as these therapies receive additional regulatory approvals.



By geographic region, as of September 30, 2026, Cryoport supported 589 trials in the Americas, 143 in EMEA, and 56 in APAC (Asia-Pacific). This compares to 559 in the Americas, 137 in EMEA, and 49 in APAC as of September 30, 2025.

Cryoport Supported Clinical Trials by Phase

Clinical Trials	September 30,		
	2024	2025	2026
Phase 1	295	309	319
Phase 2	317	353	370
Phase 3	79	83	99
Total	691	745	788

Cryoport Supported Clinical Trials by Region


Clinical Trials	September 30,		
	2024	2025	2026
Americas	531	559	589
EMEA	112	137	143
APAC	48	49	56
Total	691	745	788

During the third quarter of 2026, two (2) of our customers filed Biologics License Applications (BLA). For the remainder of 2026, we anticipate another five (5) possible BLA / Marketing Authorization Applications (MAA), two (2) possible additional new therapy approvals, and one (1) possible additional approval for geographic expansion from our customer base. Importantly, both

of the potential new therapy approvals have received PDUFA dates from the U.S. Food and Drug Administration (FDA) for Q4 2026.

During Q3 2026, Cryoport's customer, Replimune, received accelerated FDA approval for TUDRIQEV™ (vusolimogene oderparepvec-wtpg), previously referred to as RP1, in combination with nivolumab for the treatment of adults with unresectable advanced cutaneous melanoma, a skin cancer that has spread too widely or deeply to be safely or completely removed with surgery. There are limited treatment options for advanced melanoma, and more than half of patients experience progression within six months of treatment on immune checkpoint inhibitors like anti-PD-1 therapy. These patients face a poor prognosis, with a median overall survival of less than one year following progression.

Also, during the quarter Crispr Therapeutics and their partner Vertex Pharmaceuticals received FDA supplemental approval to expand the label of CASGEVY® for treatment of people *2 years of age and older* with either Sickle Cell Disease (SCD) and Transfusion-dependent Beta Thalassemia (TDT). CASGEVY is the first approved genetic therapy indicated for children as young as 2 years for both SCD and TDT .




Operational Milestones and Growth Drivers

We also achieved several important operational milestones during the quarter. Our Global Supply Chain Center in Paris received both ISO 9001 and ISO 21973 certifications. This milestone contributed to Cryoport Systems receiving the Healthcare & Pharmaceutical Supply Chain Excellence Award. We are incredibly proud of these accomplishments, which underscore our commitment to quality, innovation, and leadership in serving the life sciences industry.



Additionally, we initiated BioLogistics services at our new state-of-the-art Global Supply Chain Center located in Santa Ana, California. This facility consolidates a number of our key operations into a centralized Southern California hub near major transportation and logistics infrastructure. Combined, these two new facilities strengthen our Global Supply Chain Network, expanding our capacity to deliver advanced temperature-controlled logistics solutions to life sciences clients around the world.



As part of our continuing strategic initiatives to strengthen our growth trajectory, during the third quarter our CRYOGENE subsidiary secured new BioStorage and service contracts with customers including Houston Methodist Medical Center, Sonic Clinical Trials, and XenoSTART. In addition, CRYOGENE launched a new division, Cryogenic Technical Services (CTS), which is home to some of the most advanced engineering and manufacturing expertise in the area of mission-critical cryogenics. This dedicated division for technical services builds on CRYOGENE's expertise in mission-critical cryogenic systems and its strong footprint in the BioStorage sector, further expanding our ability to serve the evolving needs of the research, biotech, and pharmaceutical industries.

Cryoport – Keeping up the Momentum

In closing, our strong third quarter results reflect the growth trends driving our business. With **23 commercial therapies supported, a record clinical trial pipeline**, expanding customer adoption, and improving operating leverage, Cryoport is strengthening its leadership position across the CGT ecosystem.

Third Quarter 2026 Financial Results

Please refer to the Q3 2026 Earnings Release published on our website www.cryoportinc.com under *Investor Relations* for more information.

Upcoming Financial Conferences

Cryoport's management team frequently participates in financial conferences and other industry events, including virtual conferences, to ensure it is in regular communication with the investment community. Upcoming Company participations are shown in the following table:

Host	Conference	Date	Location
UBS	Global Healthcare Conference	November 8-11, 2026	Palm Beach, FL
Jefferies	Global Healthcare Conference	November 16-19, 2026	London, UK
Stephens	Annual Growth Conference	November 17-19, 2026	Nashville, TN
BTIG	Digital Healthcare Forum	November 23, 2026	Virtual
J.P. Morgan	Healthcare Conference	January 11–14, 2027	San Francisco
BTIG	MedTech Conference	February 8-10, 2027	Snowbird, UT
Roth	Annual Conference	March 7-9, 2027	Dana Point, CA

Forward-Looking Statements

Statements in this document which are not purely historical, including statements regarding the Company's intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, those related to the Company's industry, business, long-term growth prospects, plans, strategies, acquisitions, future financial results and financial condition, such as the Company's outlook and guidance for full-year 2026 revenue and the related assumptions and factors expected to drive revenue, projected growth trends in the markets in which the Company operates, the Company's plans and expectations regarding the launch of new products and services, such as the expected timing and benefits of such products and services launches, the Company's expectations about future benefits of its acquisitions, and anticipated regulatory filings, approvals, label/geographic expansions or moves to earlier lines of treatment approved with respect to the products of the Company's clients. Forward-looking statements also include those related to the Company's belief that its leadership position within the CGT ecosystem will continue to drive commercial revenue growth as CGT therapies receive additional regulatory approvals and the Company's plans to build upon CRYOGENE's established footprint in the BioStorage sector and enhance its ability to support the research, biotech, and pharmaceutical industries through CTS. It is important to note that the Company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effects of changing economic and geopolitical conditions, such as those resulting from the war with Iran, supply chain constraints, inflationary pressures, the effects of foreign currency fluctuations, trends in the products markets, variations in the Company's cash flow, market acceptance risks, the effects of tariffs and other trade restrictions, and technical development risks. The Company's business could be affected by other factors discussed in the Company's SEC reports, including in the "Risk Factors" section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC. The forward-looking statements contained in this document speak only as of the date hereof and the Company cautions investors not to place undue reliance on these forward-looking statements. Except as required by law, the Company disclaims any obligation and does not undertake to update or revise any forward-looking statements in this document.

About Cryoport, Inc.

Cryoport, Inc. (Nasdaq: CYRX), is a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, with an emphasis on regenerative medicine. We support biopharmaceutical companies, contract manufacturers (CDMOs), contract research organizations (CROs), developers, and researchers with a comprehensive suite of services and products designed to minimize risk and maximize reliability across the temperature-controlled supply chain for the life sciences. Our integrated supply chain platform includes the Cryoportal® Logistics Management Platform, advanced temperature-controlled packaging, informatics, specialized BioLogistics, BioStorage, BioServices, cryopreservation services, and cryogenic systems, which in varying combinations deliver end-to-end solutions that meet the rigorous demands of the life sciences. With innovation, regulatory compliance, and agility at our core, we are ***"Enabling the Future of Medicine™."***

Headquartered in Nashville, Tennessee, our company maintains a strong global presence with operations across the Americas, EMEA, and APAC.

For more information, visit www.cryoportinc.com or follow via LinkedIn at https://www.linkedin.com/company/cryoportinc or @cryoport on X, formerly known as Twitter at www.x.com/cryoport for live updates.